Hims & Hers Health Inc. (HIMS) stock soared 5.11% in the pre-market trading session on Tuesday. This significant surge can be attributed to the initiation of bullish analyst coverage by BTIG.
BTIG initiated coverage on Hims & Hers Health with a "Buy" rating and a price target of $35, citing the company's disruptive approach to healthcare using technology and convenience. The analyst firm praised Hims & Hers for offering access to medications and personalized treatment plans, insulating it from the risk of patients returning to in-person visits.
Furthermore, BTIG highlighted the company's potential for robust revenue growth and increasing demand for its GLP-1 and other obesity health products, such as compounded versions of Novo Nordisk's Wegovy and Ozempic. The firm believes that the compounding trend for GLP-1s is likely to continue, boding well for Hims & Hers Health's future prospects.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.